Are You Ready For the Upcoming USP-800 Deadline?

Tuesday, April 2, 2019
1PM ET/ 12PM CT

Long-term care patients with dysphagia do not always have FDA-approved liquid suspensions available. When tablets are crushed or compounded, the formulations can put them in danger, as the dosing consistency and efficacy can change.
The FDA has issued strict guidance about using FDA-approved forms. Additionally, new regulations (USP-800) starting in December 2019 will create stricter rules on how to crush and compound tablets and will have stricter guidelines on crushing/compounding tablets in order to remain compliant.

Attendees will learn: 

  • How to understand dysphagia, a condition that causes difficulty swallowing and can make it difficult for patients to swallow solid-dose medication.
  • Discuss concerns about non-compliant compounding practices.
  • Review FDA guidelines about crushing and compounding tablets when FDA approved liquids are available
  • Discover how some crushed/compounded formulations are not FDA-approved and are not tested for accuracy, safety, and potency.
  • Improve resident safety by providing accurate and consistent dosing while avoiding giving the wrong dose of medication. 
Presenter
Dr. Albert Riddle MD, CMD
President and CEO
Riddle Medical Group, P.L.L.C.
View Biography

Registration details:

By registering you are accepting our Privacy Policy and Terms of Use.

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

Submit